[1]梁 钢.造影剂肾病的诊治进展[J].医学信息,2018,31(04):45-49,52.[doi:10.3969/j.issn.1006-1959.2018.04.015]
 LIANG Gang.Progress in Diagnosis and Treatment of Contrast Nephropathy[J].Journal of Medical Information,2018,31(04):45-49,52.[doi:10.3969/j.issn.1006-1959.2018.04.015]
点击复制

造影剂肾病的诊治进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年04期
页码:
45-49,52
栏目:
综述
出版日期:
2018-02-15

文章信息/Info

Title:
Progress in Diagnosis and Treatment of Contrast Nephropathy
文章编号:
1006-1959(2018)04-0045-06
作者:
梁 钢
天津市第一中心医院国际诊疗中心老年内科,天津 300192
Author(s):
LIANG Gang
Department of Geriatrics,International Diagnosis and Treatment Center,First Central Hospital of Tianjin,Tianjin 3001922,China
关键词:
造影剂肾病危险因素预防
Keywords:
Key words:Contrast nephropathyRisk factorsPrevention
分类号:
R692
DOI:
10.3969/j.issn.1006-1959.2018.04.015
文献标志码:
A
摘要:
造影剂肾病已成为当前医院内发生肾功能衰竭的第三位常见原因,并且发病率和死亡率逐年增加。虽然造影剂肾病在普通人群中发病风险并不高,但在具有高危因素的人群中,比如原有肾功能不全、糖尿病和行急诊经皮冠脉介入治疗等,造影剂肾病的发病风险明显增高。造影剂肾病的主要发病机制是肾髓质缺血,另外,氧自由基损害、免疫因素、肾小管阻塞等也有重要作用。尿中性粒细胞明胶酶载脂蛋白和肾损伤分子1是诊断造影剂早期肾损伤敏感且特异性较高的指标。水化治疗可预防造影剂肾病的发生。本文将对造影剂肾病的发病机制、危险因素、临床过程以及预防、治疗措施进行综述。
Abstract:
Abstract:Contrast nephropathy has become the third most common cause of renal failure in hospitals,and the morbidity and mortality are increasing year by year.Although the risk of renal failure in the general population is not high, in the population with high risk factors,such as original renal insufficiency,diabetes and emergency percutaneous coronary intervention,the risk of contrast agent nephropathy was significantly increased.The main pathogenesis of contrast agent nephropathy is renal medullary ischemia,in addition,oxygen free radical damage, immune factors.Tubular obstruction also has an important role.Urinary neutrophil gelatinase apolipoprotein and renal injury molecule 1 are sensitive and specific indicators for the early diagnosis of contrast-induced renal injury.Hydration therapy can prevent the occurrence of contrast agent nephropathy.This article will review the pathogenesis of contrast agent nephropathy,risk factors,clinical course, as well as prevention and treatment measures.

参考文献/References:

[1]Solomon R,Dauerman H L.Contrast-Induced Acute Kidney Injury[J].Clinical Queries Nephrology,2010,1(1):34-41.
[2]Tsai TT,Patel UD,Chang TI,et al.Contemporary incidence, predictors,and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry[J].JACC Cardiovasc Interv,2014,7(1):1-9.
[3]Lencioni R,Fattori R,Morana G,et al.Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT)- a clinical problem in daily practice A multicenter observational study[J].Acta Radiol,2010,51(7):741-750.
[4]Nicola R,Shaqdan KW,Aran K,et al.Contrast-Induced Nephropathy:Identifying the Risks,Choosing the Right Agent, and Reviewing Effective Prevention and Management Methods[J].Curr Probl Diagn Radiol,2015,44(6):501-504.
[5]Reiner Z,Catapano AL,De Backer G,et al.ESC/EAS Guidelines for the management of dyslipidaemias[J].Rev Esp Cardiol,2011,64(12):1168.
[6]Fukushima Y,AUID- Oho,Miyazawa H,et al.Contrast-induced nephropathy(CIN)of patients with renal dysfunction in CT examination[J].Jpn J Radiol,2017,35(8):427-431.
[7]李辉,刘兵,赵迎,等.老年患者冠状动脉造影术后对比剂肾病发生率及危险因素分析[J].中华老年医学杂志,2015,34(9):935-938.
[8]Davenport MS,Khalatbari S,Cohan RH,et al.Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material:risk stratification by using estimated glomerular filtration rate[J].Radiology,2013,268(3):719-728.
[9]Kumar S,Nair RK,Aggarwal N,et al.Risk factors for contrast-induced nephropathy after coronary angiography[J].Saudi J Kidney Dis Transpl,2017,28(2):318-324.
[10]张萍,张虹,曹振华,等.急性冠脉综合征患者 PCI 术后造影剂肾病危险因素分析[J].山东医药,2014,54(17):64-66.
[11]陈纪言,谭宁,刘勇,等.冠状动脉慢性闭塞患者行心导管术后发生造影剂肾病的风险预测模型[J].中华内科杂志,2015,54(4):343.
[12]周希,余红.血糖与冠状动脉介入治疗后造影剂肾病的相关性[J].中国老年学, 2014,34(14):3861-3862.
[13]杨清,张建维,杨士伟,等.术前血糖水平对急诊冠状动脉介入治疗后造影剂肾病发生率的影响[J].中华老年多器官疾病杂志,2013,12(4):249-253.
[14]刘远辉,谭宁,刘勇,等.高尿酸血症与慢性肾脏疾病患者经皮冠状动脉介入治疗后对比剂肾病的相关性[J].中华心血管病杂志,2013,41(9):740-743.
[15]林晓强,朱海,詹源胜.围术期血红蛋白下降与心导管术后发生造影剂肾病的相关性[J].岭南心血管病杂志,2014,20(4):526-529.
[16]翟婷婷,刘孟春,刘雪梅,等.肾素-血管紧张素系统阻滞剂与造影剂肾病发生的Meta分析[J].中华肾脏病杂志,2016,32(5):350-357.
[17]Morales M G,Abrigo J,Meneses C,et al.The Ang-(1-7)/Mas-1 axis attenuates the expression and signalling of TGF-β1 induced by AngII in mouse skeletal muscle[J].Clinical Science,2014,127(4):251-264.
[18]鄢高亮,孔文杰,王栋,等.血浆同型半胱氨酸水平对急性冠状动脉综合征患者介入治疗后对比剂肾病的影响[J].中华心血管病杂志,2016,44(1):32-37.
[19]Ludwig U,Connemann J,Keller F.Effect of low-osmolar contrast medium iopromide and iso-osmolar iodixanol on DNA fragmentation in renal tubular cell culture[J].Clin Exp Nephrol, 2013,17(6):779-782.
[20]Gohbara M,Hayakawa A,Akazawa Y,et al.Association Between Acidosis Soon After Reperfusion and Contrast-Induced Nephropathy in Patients With a First-Time ST-Segment Elevation Myocardial Infarction[J].Journal of the American Heart Association Cardiovascular&Cerebrovascular Disease,2017,6(8):e006380.
[21]Burchardt P,Guzik P,Tabaczewski P,et al.Early renal dysfunction after contrast media administration despite prophylactic hydration[J].International Journal of Cardiovascular Imaging,2013,29(5):959-966.
[22]de Bruyn M,Arijs I,De Hertogh G,et al.Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease[J].J Crohns Colitis,2015,9(12):1079-1087.
[23]王磊,蒲晓群.冠状动脉介入诊疗术后尿中性粒细胞明胶酶相关性载脂蛋白和肾损伤分子1水平的变化及早期预测对比剂肾病的价值[J].中华心血管病杂志,2014,42(4):301-304.
[24]尤威,戚晨良,叶飞,等.尿中性粒细胞明胶酶相关脂质运载蛋白对对比剂肾病的早期诊断价值[J].中华心血管病杂志,2016,44(12):1024-1029.
[25]Martensson J,Bell M,Xu S,et al.Association of plasma neutrophil gelatinase-associated lipocalin(NGAL)with sepsis and acute kidney dysfunction[J].Biomarkers,2013,18(4):349-56.
[26]朱润章,郝丽,王德光,等.造影剂早期肾损伤的诊断及水化治疗的防护作用[J].中华肾脏病杂志,2014,30(1):24-28.
[27]Schinstock CA,Semret MH,Wagner SJ,et al.Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury[J].Nephrol Dial Transplant,2013,28(5):1175-85.
[28]李明珠,张金盈,沈德良.冠状血管造影术前血浆氨基末端脑钠肽前体水平与造影剂肾病发生的相关性研究[J].中国全科医学,2014,17(3):278-281.
[29]何谊婷,谭宁,刘远辉,等.高敏C反应蛋白与经皮冠状动脉介入治疗患者对比剂肾病的相关性[J].中华心血管病杂志,2013,41(5):394-398.
[30]张博晴,孙烈,杨季明,等.血清视黄酸结合蛋白与冠状动脉造影后造影剂肾病发生相关性的研究[J].中国医药科学,2013,(22):30-31,59.
[31]刘军,陈新军,姬新才.血清半胱蛋白酶抑制素C检测对脑血管造影术患者发生对比剂肾病的诊断价值[J].陕西医学杂志,2014,(6):667-668.
[32]周杰,汪坤,李必龙,等.血清胱抑素C与脑利钠肽联合检测在对比剂肾病早期诊断中的临床意义[J].中国基层医药,2014,(z1):1-3.
[33]余振球,段绍斌,周顺科,等.尿肾脏损伤分子1、白细胞介素18和胱抑素C对老年钆造影剂肾病的预测价值[J].中华肾脏病杂志,2013,29(3):173-177.
[34]彭莉,黄嘉南,赵崇亮,等.胱抑素C在经皮冠状动脉介入治疗术后造影剂肾病诊断中的价值[J].中华内科杂志,2015,54(3):188-192.
[35]鄢高亮,侯建同,沙翔,等.血小板与淋巴细胞比值对老年急性心肌梗死患者冠状动脉介入术后造影剂肾病发生的预测价值[J].中华老年医学杂志,2016,35(8):828-833.
[36]Kocas C,Yildiz A,Abaci O,et al.Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome[J].Angiology, 2015,66(10):964-968.
[37]Richter SK,Crannage AJ.Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy[J].J Community Hosp Intern Med Perspect,2015,5(3):27297.
[38]朱润章,郝丽,王德光,等.造影剂早期肾损伤的诊断及水化治疗的防护作用[J].中华肾脏病杂志,2014,30(1):24-28.
[39]Sato A,Hoshi T,Aonuma K.No prophylaxis is non-inferior and cost-saving to prophylactic intravenous hydration in preventing contrast-induced nephropathy on requiring iodinated contrast material administration[J].J Thorac Dis,2017,9(6):1440-1442.
[40]李绍钦,王凯,田丰,等.血管造影剂对老年缺血性脑血管病患者肾功能影响的临床观察[J].中华老年医学杂志,2014,33(3):250-253.
[41]Briguori C,Visconti G,Donahue M,et al.RenalGuard system in high-risk patients for contrast-induced acute kidney injury[J].Am Heart J,2016(173):67-76.
[42]方国英,蒋建敏,张晓燕,等.N-乙酰半胱氨酸对老年患者碘海醇肾损害的保护作用[J].浙江医学,2013,35(14):1345-1347.
[43]乔英,杨世诚,付乃宽.N-乙酰半胱氨酸对老年冠心病患者介入治疗后造影剂肾病的预防作用[J].中华老年心脑血管病杂志,2013,15(4):339-342.
[44]耿雪,张凯,崔炜.术前大剂量他汀类药物预防对比剂肾病的meta分析[J].临床荟萃,2014,29(1):5-9.
[45]全军民,邱樑,陶袁,等.阿托伐他汀对老年糖尿病患者行造影术后肾功能的影响[J].新医学,2014,45(8):542-546.
[46]Layton JB,Kshirsagar AV,Simpson RJ Jr,et al.Effect of statin use on acute kidney injury risk following coronary artery bypass grafting[J].Am J Cardiol,2013,111(6):823-828.
[47]Syed MH,Khandelwal PN,Thawani VR,et al.Efficacy of Atorvastatin in Prevention of Contrast-induced Nephropathy in High-risk Patients Undergoing Angiography:A Double-blind Randomized Controlled Trial[J].J Pharmacol Pharmacother,2017,8(2):50-53.
[48]陆锐,邓可武,张文超,等.强化他汀类药物治疗预防造影剂肾病的对比研究[J].中国医药,2016,11(7):1043-1046.
[49]马延峰,李文华,李东野,等.贝前列素钠对冠心病患者介入术后对比剂肾病的预防作用[J].中国医药指南,2013,(32):30-32.
[50]王静,彭永平,宫剑滨,等.前列地尔对冠心病合并糖尿病患者介入治疗后造影剂肾病的影响[J].东南国防医药,2014,16(1):28-30.
[51]刘春斌,李凯,黄松.低渗非离子型造影剂对2型糖尿病及Ⅰ~Ⅲ期糖尿病肾病患者肾功能的影响研究[J].中国全科医学,2014,17(17):1969-1972.
[52]庞敏,贺心良,张海燕,等.碳酸氢钠水化疗法对造影剂肾病预防[J].中外健康文摘,2014,(9):152.
[53]段丙军,黄乐,丁红,等.姜黄素预诱导血红素氧合酶1表达防治对比剂肾病的实验研究[J].中华心血管病杂志,2013,41(2):116-120.
[54]Ghelich K Z,Talasaz A H,Pourhosseini H,et al.Potential Role of Allopurinol in Preventing Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial.[J].Clinical Drug Investigation,2017(10):1-8.
[55]Gholoobi A,Sajjadi SM,Shabestari MM,et al.The Impact of Remote Ischemic Pre-Conditioning on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography and Angioplasty:A Double-Blind Randomized Clinical Trial[J]. Electron Physician,2015,7(8):1557-1565.
[56]吴际,王乃平,赵静瑜.连续性血液透析滤过对造影剂肾病预防作用的临床观察[J].中国中西医结合肾病杂志,2016,17(7):614-616.
[57]胡越成,张琦,丛洪良.曲美他嗪对心肾功能的保护作用[J].中华老年心脑血管病杂志, 2013,15(1):98-101.

相似文献/References:

[1]廖加群,曹 雪,陈燕平,等.宫颈癌盆腔淋巴结转移分布及危险因素分析[J].医学信息,2018,31(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
 LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Journal of Medical Information,2018,31(04):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]翟公伟,赵培华,滑 艳.30岁以下急性ST段抬高型心肌梗死患者临床特点分析[J].医学信息,2018,31(05):81.[doi:10.3969/j.issn.1006-1959.2018.05.026]
 ZHAI Gong-wei,ZHAO Pei-hua,HUA Yan.Clinical Characteristics of Acute ST-segment Elevation Myocardial Infarction under 30 Years of Age[J].Journal of Medical Information,2018,31(04):81.[doi:10.3969/j.issn.1006-1959.2018.05.026]
[3]孙 志,邢效如,揣兰香,等.青年脑出血患者的临床特点及发病危险因素分析[J].医学信息,2018,31(06):80.[doi:10.3969/j.issn.1006-1959.2018.06.025]
 SUN Zhi,XING Xiao-ru,CHUAI Lan-xiang,et al.Analysis of Clinical Features and Risk Factors of Cerebral Hemorrhage in Youth[J].Journal of Medical Information,2018,31(04):80.[doi:10.3969/j.issn.1006-1959.2018.06.025]
[4]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
 XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Journal of Medical Information,2018,31(04):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[5]单菲菲,陈 琴,吕建国,等.体力活动与子宫内膜癌关系的病例对照研究[J].医学信息,2018,31(10):62.[doi:10.3969/j.issn.1006-1959.2018.10.019]
 SHAN Fei-fei,CHEN Qin,LV Jian-guo,et al.Case Control Study on the Relationship between Physical Activity and Endometrial Carcinoma[J].Journal of Medical Information,2018,31(04):62.[doi:10.3969/j.issn.1006-1959.2018.10.019]
[6]韩 倩,刘 兴.脑小血管病诊疗进展[J].医学信息,2018,31(11):52.[doi:10.3969/j.issn.1006-1959.2018.11.017]
 HAN Qian,LIU Xing.Progress in Diagnosis and Treatment of Small Cerebral Vascular Disease[J].Journal of Medical Information,2018,31(04):52.[doi:10.3969/j.issn.1006-1959.2018.11.017]
[7]何广宾,左海涛,陈永青.呼吸机相关性肺炎对急性呼吸窘迫综合征患者预后的影响[J].医学信息,2022,35(11):89.[doi:10.3969/j.issn.1006-1959.2022.11.023]
 HE Guang-bin,ZUO Hai-tao,CHEN Yong-qing.Effect of Ventilator Associated Pneumonia on Prognosis of Patients with Acute Respiratory Distress Syndrome[J].Journal of Medical Information,2022,35(04):89.[doi:10.3969/j.issn.1006-1959.2022.11.023]
[8]俞 瑞,吴建荣,杨晓萍,等.健康体检者中高尿酸人群血脂水平变化及 甘油三脂升高的相关因素分析[J].医学信息,2018,31(13):62.[doi:10.3969/j.issn.1006-1959.2018.13.018]
 YU Rui,WU Jian-rong,YANG Xiao-ping,et al.Analysis of Related Factors of Blood Lipid Levels and Elevated Triglycerides in Hyperuricemia Population in Healthy Subjects[J].Journal of Medical Information,2018,31(04):62.[doi:10.3969/j.issn.1006-1959.2018.13.018]
[9]谢凌燕.汉川市第二人民医院工作人员职业暴露危险因素分析 及防护措施[J].医学信息,2018,31(15):173.[doi:10.3969/j.issn.1006-1959.2018.15.058]
 XIE Ling-yan.Analysis of Occupational Exposure Risk Factors and Protective Measures for Staff of the Second People's Hospital of Hanchuan City[J].Journal of Medical Information,2018,31(04):173.[doi:10.3969/j.issn.1006-1959.2018.15.058]
[10]李新刚.抗结核药物治疗所致肝损伤患者的危险因素及其治疗转归观察[J].医学信息,2019,32(03):155.[doi:10.3969/j.issn.1006-1959.2019.03.051]
 LI Xin-gang.Risk Factors and Treatment Outcomes of Patients with Liver Injury Caused by Anti-tuberculosis Drugs[J].Journal of Medical Information,2019,32(04):155.[doi:10.3969/j.issn.1006-1959.2019.03.051]

更新日期/Last Update: 2018-02-15